Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan

International Journal of Hematology

Volumn 88, Issue 2, 2008, Pages 154-158

  Narimatsu, Hiroto ^a,b   Iino, Masaki ^c   Ichihashi, Takuji ^d   Yokozawa, Toshiya ^e   Hayakawa, Masaya ^f   Kiyoi, Hitoshi ^g   Takeo, Takaaki ^h   Sawamoto, Akiyo ^a   Iida, Hiroatsu ⁱ   Tsuzuki, Motohiro ^j   Yanada, Masamitsu ^b   Naoe, Tomoki ^b   Suzuki, Ritsuro ^g   Sugiura, Isamu ^a  

^a TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Yamanashi Prefectural Central Hospital   (Japan)

^d Okazaki City Hospital   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^f KOMAKI CITY HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h Yokkaichi Municipal Hospital   (Japan)

ⁱ Meitetsu Hospital   (Japan)

^j FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute myeloid leukemia; Minimal residual disease; Prognosis; RUNX MTG8; t(8; 21)

Indexed keywords

CYTARABINE; DAUNORUBICIN; IDARUBICIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; GENE DOSAGE; HUMANS; IDARUBICIN; JAPAN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS;

EID: 56649123407     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0108-1     Document Type: Article

References (16)

1. F Ferrara L Del Vecchio 2002 Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity Haematologica 87 306 19
2. D Grimwade H Walker F Oliver 1998 The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 2322 33
3. JC Byrd K Mrozek RK Dodge 2002 Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) Blood 100 4325 36
4. CA Heid J Stevens KJ Livak PM Williams 1996 Real time quantitative PCR Genome Res 6 986 94
5. J Krauter K Gorlich O Ottmann 2003 Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 4413 22
6. K Tobal J Newton M Macheta 2000 Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse Blood 95 815 9
7. H Leroy S de Botton N Grardel-Duflos 2005 Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) Leukemia 19 367 72
8. G Perea A Lasa A Aventin 2006 Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] Leukemia 20 87 94
9. M Weisser C Haferlach W Hiddemann S Schnittger 2007 The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors Leukemia 21 1177 82
10. H Narimatsu T Yokozawa H Iida 2008 Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan Leukemia 22 428 32
11. G Marcucci K Mrozek AS Ruppert 2005 Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study J Clin Oncol 23 5705 17
12. K Osumi T Fukui H Kiyoi 2002 Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR Leuk Lymphoma 43 2291 9
13. T Nanri N Matsuno T Kawakita 2005 Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22) Leukemia 19 1361 6
14. S Schnittger TM Kohl T Haferlach 2006 KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 1791 9
15. P Paschka G Marcucci AS Ruppert 2006 Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study J Clin Oncol 24 3904 11
16. T Miyamoto IL Weissman K Akashi 2000 AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation Proc Natl Acad Sci USA 97 7521 6